A Diabetic Foot Ulcer with a Positive Probe-to-Bone Test and an MRI Ten Days Away
A 58-year-old man with type 2 diabetes (A1c 8.9%) has a 4-cm ulcer over the first metatarsal head present for 6 weeks. A sterile probe reaches firm bone. He is afebrile with a white count of 9,800/µL, ESR 76 mm/h, and CRP 58 mg/L. Plain films show no definite erosion. There is no fluctuance, no exposed bone, no foul odor, and no tracking. Pedal pulses are 2+ bilaterally with an ABI of 1.05; he has no rest pain or gangrene. An MRI ordered elsewhere is scheduled in 10 days. He asks whether he can simply take pills in the meantime, and whether he really needs the MRI at all.
1. Does he need the MRI or a bone biopsy before starting antibiotics? Explain your reasoning.
Read the worked answer
A probe-to-bone test that reaches bone in a diabetic foot ulcer has a high positive predictive value for osteomyelitis, and the combination of a 6-week ulcer, positive probe, and ESR of 76 makes the post-test probability high enough to treat clinically.
The MRI is optional here, not mandatory. It changes management when the diagnosis is genuinely uncertain, when the extent of bone and soft-tissue involvement will guide resection, when abscess or deep-space infection is suspected, or when Charcot arthropathy or another process is a real alternative. In this man - no fluctuance, no exposed bone, preserved perfusion, no systemic toxicity, and a plain film without erosion - the MRI is unlikely to change the decision to treat, though it would be reasonable before any planned surgery or if he fails to improve.
Microbiology is the more valuable step. Obtain a specimen before antibiotics if at all possible: a bone specimen at debridement is the reference standard, and a properly obtained deep wound curettage or biopsy is far better than a superficial swab. If no debridement is planned, deep sampling followed by prompt empiric therapy covering staphylococci and streptococci is appropriate. Do not delay antibiotics in a limb-threatening or systemically unwell patient; that situation does not apply here.
2. Would you choose oral or intravenous antibiotics, and which agents? What determines duration and success?
Read the worked answer
Oral therapy is reasonable and preferred if he can take it. With intact perfusion (ABI 1.05), no deep-space or limb-threatening infection, and a reliable patient, oral antibiotics with good bone penetration achieve outcomes noninferior to intravenous therapy - the OVIVA trial randomized patients with bone and joint infection, including diabetic foot osteomyelitis, to early oral therapy and found noninferiority. Intravenous therapy would be justified by ischemia requiring revascularization, spreading cellulitis, sepsis, an undrained abscess, or inability to take enteral medication.
Regimen: cover S. aureus and beta-hemolytic streptococci; add gram-negative coverage for a chronic ulcer. Reasonable choices are amoxicillin-clavulanate 875/125 mg twice daily, or levofloxacin plus clindamycin if penicillin allergy. Add MRSA coverage (e.g., trimethoprim-sulfamethoxazole) if there is prior MRSA, recent hospitalization, or failure to improve. Avoid rifampin unless there is retained hardware.
Duration: about 6 weeks for medical management of residual osteomyelitis; shorter if all infected bone is resected. The two interventions that most determine success are not the antibiotics at all - they are offloading (total contact cast or equivalent, non-weight-bearing) and glycemic control. Refer to podiatry and vascular surgery. Reassess at 2–4 weeks; persistent wound, rising markers, or new bone destruction means surgical debridement and repeat deep cultures, not simply a switch of oral agent.